BERLIN: AMP German Cannabis Group is developing medical brands for a range of cannabis flower strains, extracts and other novel dosage forms specifically for the German market supplied by foreign licenced medical cannabis producers.

Licensed producers that have been EU-GMP certified will cultivate medical cannabis to AMP’s brand specifications and quality standards.

First large imports of AMP’s medical cannabis brand are expected to be coming from Canada during the fall of 2020 from licenced producersthat were EU-GMP certified prior to COVID-19 pandemic. AMP only enters into supply agreements with Canadian licenced producers who can supply a minimum of 1,000 kg annually of AMP branded medical cannabis, shipped on a monthly basis.

AMP is in negotiations with several Canadian licenced producers to begin shipments in the fall of this year.

AMP is advancing its other signed Canadian producers to be EU-GMP audited during the fall of 2020 by the Company’s German pharmaceutical consultant and inspected for certification during early 2021 by TLV (the Thuringian State Office for Consumer Protection) provided international travel restrictions are normalized.

To meet future demand as the German market grows, AMP is developing long-term supply sources in Europe for large scale supply of AMP medical cannabis branded products.

The Company believes as the German market develops, Europe will become an important and significant medical cannabis supply source.

AMP’s strategy is to develop exclusive relationships with large medical cannabis licenced producers in certain EU countries for AMP medical cannabis branded products for the German market.

AMP’s non-exclusive distribution agreement (see press release dated 16th October 2019) with a leading distributor of pharmaceuticals products to more than 13,000 pharmacies throughout Germany encompasses purchasing AMP medical cannabis branded products.

In addition, AMP will be investing in physician and pharmacist’s education seminars across Germany about medical cannabis.

The Company is also in negotiations with additional pharmaceutical distributors to purchase AMP medical cannabis branded products as AMP’s imports increases this fall.

Dr. Stefan Feuerstein, Director of AMP, commented: “We had hoped to fulfill our distribution agreement with our lead pharmaceutical distributor in regards to imports from the Netherlands this month but we are optimistic that the Netherlands will resolve its export quota to Germany and increase exports in the near future.

As already mentioned, we are in advanced negotiations with several foreign cannabis producers who already have an EU-GMP certification and are expecting to sign at least one definitive supply agreement within the next four weeks.

Beginning this fall, AMP will be selling AMP branded medical cannabis products imported from Canada into Germany.”